Loading...
Docoh

Dare Bioscience (DARE)

News

From Benzinga Pro
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
12 May 22
Biotech, Earnings, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Dare Bioscience: Q1 Earnings Insights
12 May 22
Earnings, News
Dare Bioscience (NASDAQ:DARE) reported its Q1 earnings results on Thursday, May 12, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Dare Bioscience Q1 EPS $(0.10) Beats $(0.14) Estimate
12 May 22
Earnings, News
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 41.18 percent increase over losses of $(0.17) per share from
Earnings Scheduled For May 12, 2022
12 May 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.
Earnings Preview: Dare Bioscience
11 May 22
Earnings
Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that Dare Bioscience will report an earnings per share (EPS) of $-0.14.
Dare Bioscience Reports Notice Of Award Of Grant From Eunice Kennedy Shriver National Institute Of Child Health For ~$249K 'to support end-user research, including surveys of approximately 1,000 women in the U.S. ages 18-44 years...'
11 May 22
Biotech, News, FDA, General
Supports research to define end-user preferences among U.S. women to inform the design of long-acting injectable hormonal contraception Daré is developing novel injectable formulations of etonogestrel designed to
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
4 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Wednesday's trading, 435 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Daré Bioscience Initiates Phase 1/2 Clinical Study Of DARE-HRT1
12 Apr 22
Biotech, News, FDA, General
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1. DARE-HRT1 is a novel intravaginal ring (IVR)
HC Wainwright & Co. Maintains Buy on Dare Bioscience, Raises Price Target to $6
1 Apr 22
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Dare Bioscience (NASDAQ:DARE) with a Buy and raises the price target from $5 to $6.
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
31 Mar 22
Biotech, Earnings, News, Penny Stocks, Guidance, Health Care, Contracts, Movers, Trading Ideas, General
Organon & Co (NYSE: OGN)
Recap: Dare Bioscience Q4 Earnings
31 Mar 22
Earnings
Dare Bioscience (NASDAQ:DARE) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Organon Enters Into Global License Agreement To Commercialize Daré Bioscience's XACIATO, FDA-Approved Treatment For Females 12 And Older With Bacterial Vaginosis
31 Mar 22
Biotech, News, Contracts, General
Organon (NYSE:OGN), a global women's healthcare company, and Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced they have entered into an agreement whereby Organon
Earnings Scheduled For March 31, 2022
31 Mar 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter.
Earnings Preview: Dare Bioscience
30 Mar 22
Earnings
Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Dare Bioscience will report an earnings per share (EPS) of $-0.15.